Your browser doesn't support javascript.
loading
Reprogramming RNA processing: an emerging therapeutic landscape.
Neil, Christopher R; Seiler, Michael W; Reynolds, Dominic J; Smith, Jesse J; Vaillancourt, Frédéric H; Smith, Peter G; Agrawal, Anant A.
Afiliação
  • Neil CR; Remix Therapeutics, Cambridge, MA, USA.
  • Seiler MW; Remix Therapeutics, Cambridge, MA, USA.
  • Reynolds DJ; Remix Therapeutics, Cambridge, MA, USA.
  • Smith JJ; Remix Therapeutics, Cambridge, MA, USA.
  • Vaillancourt FH; Remix Therapeutics, Cambridge, MA, USA.
  • Smith PG; Remix Therapeutics, Cambridge, MA, USA.
  • Agrawal AA; Remix Therapeutics, Cambridge, MA, USA. Electronic address: aagrawal@remixtx.com.
Trends Pharmacol Sci ; 43(5): 437-454, 2022 05.
Article em En | MEDLINE | ID: mdl-35331569
ABSTRACT
The production of a mature mRNA requires coordination of multiple processing steps, which ultimately control its content, localization, and stability. These steps include some of the largest macromolecular machines in the cell, which were, until recently, considered undruggable due to their biological complexity. Building from an expanded understanding of the underlying mechanisms that drive these processes, a new wave of therapeutics is seeking to target RNA processing. With a focus on impacting gene regulation at the RNA level, such modalities offer potential for sequence-specific resolution in drug design. Here, we review our current understanding of RNA-processing events and their role in gene regulation, with a focus on the therapeutic opportunities that have emerged within this landscape.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Processamento Pós-Transcricional do RNA / Oligonucleotídeos Antissenso Limite: Humans Idioma: En Ano de publicação: 2022 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Processamento Pós-Transcricional do RNA / Oligonucleotídeos Antissenso Limite: Humans Idioma: En Ano de publicação: 2022 Tipo de documento: Article